Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method - Concepedia

Concepedia

Publication | Open Access

Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method

DOI Full Paper Access

44

Citations

39

References

2011

Year

Elena García-García, Carlos Gómez-Martín, Bárbara Angulo, Esther Conde, Ana Suárez‐Gauthier, Magdalena Adrados, Cristian Perna, José Luis Rodríguez‐Peralto, Manuel Hidalgo, Fernando López‐Ríos

Abstract

Dual-colour SISH represents a novel method for the determination of HER2 status in GC.

References

	Year	Citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong, Science	1987	11.6K
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova, The Lancet Surgical OncologyChemotherapy Versus ChemotherapyGastrointestinal OncologyMedicineGastroenterology	2010	7.2K
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMA P Laurén Acta Pathologica Microbiologica Scandinavica So‐called Intestinal‐type CarcinomaEsophageal CancerGastrointestinal OncologyMedicineSurgical Pathology	1965	6.1K
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, Journal of Clinical Oncology	2006	4.5K
Assessment of a HER2 scoring system for gastric cancer: results from a validation study Manfred Hofmann, Di Shi, Reinhard Büttner, Histopathology	2008	1.2K
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges Sumithra J. Mandrekar, Daniel J. Sargent Journal of Clinical Oncology	2009	389
Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab R. Mass, Michael F. Press, Steven M. Anderson, Clinical Breast Cancer Her2 DetectionBreast OncologyCancer DetectionMedicinePathology	2005	364
Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Raymond R. Tubbs, James Pettay, Patrick C. Roche, Journal of Clinical Oncology	2001	362
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients Marick Laé, J Couturier, Stéphane Oudard, Annals of Oncology	2009	220
HER-2 amplification is highly homogenous in gastric cancer Andreas H. Marx, Lars Tharun, Johanna Muth, Human Pathology Tumor BiologyGastrointestinal OncologyMedicinePathologyGastric Cancer	2009	206

Page 1